Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk
Conditions
Alcohol-related Disorders | Tobacco Use Cessation
Trial Phase
Phase 2
Trial Purpose and Description
Trial Purpose
The majority of individuals with alcohol problems remain current smokers, and the negative health consequences of smoking among these individuals are substantial. This study will investigate the impact of smoking cessation interventions initiated during intensive alcohol treatment on processes reflecting risk of alcohol relapse.
Trial Description
Objectives:
Most alcohol and drug treatment programs do not systematically address cigarette smoking during treatment. One obstacle is a concern that smoking cessation early in recovery might increase risk of alcohol relapse. This study will follow patients enrolled in intensive outpatient alcohol treatment to compare the effects of a Concurrent Smoking Cessation (CSC) intervention to a Deferred Smoking Cessation (DSC) control group on process measures reflecting risk of alcohol relapse.
Research Design:
Participants will be enrolled in intensive outpatient alcohol treatment and then randomized to CSC or DSC groups in a 2:1 ratio. The CSC group will receive smoking treatment concurrent with intensive alcohol treatment and the DSC group will receive smoking treatment three months after alcohol treatment. The smoking treatment protocol will include behavioral counseling, contingency management with voucher rewards for verified smoking abstinence, and prescribed nicotine patch and gum. During a three-month period after the CSC target smoking quit date, both groups of subjects will be asked to participate in a prospective daily monitoring procedure, calling into an Interactive Voice Response system once a day to complete self-report assessments of relapse risk factors. By comparing participants in the CSC group composed of many participants who have stopped smoking with the DSC group who are expected to continue smoking during this daily monitoring period, we will determine the impact of smoking cessation on alcohol relapse risk factors.
- Methodology:
This study will be conducted in the substance abuse day treatment programs located at Newington and West Haven campuses of VA Connecticut Healthcare System. These are three-week treatment programs meeting Monday-Friday for 4-5 hrs/day. Participants may be recruited either before or soon after day program admission. Participants will be 144 individuals that are 18 years of age or older, meet DSM-IV diagnostic criteria for current alcohol abuse or dependence, report currently smoking 10 or more cigarettes per day, and are screened for medical contraindications for nicotine patch and gum use. Dependent variables are process assessments reflecting alcohol relapse risk obtained using daily Interactive Voice Response (IVR) technology. These relapse risk processes include alcohol craving, negative affect, alcohol abstinence self efficacy, alcohol outcome expectancies, motivation for alcohol abstinence, and self-control demands. Given the mixed results from previous clinical trials, we will conduct bidirectional tests of the hypothesis that smoking cessation has an impact on alcohol relapse risk factors, examining whether smoking cessation leads to increased or decreased alcohol relapse risk.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Eligibility Criteria
Inclusion Criteria:
- DSM-IV criteria for alcohol abuse or dependence
- Age 18 or older
- English speaking
- Smoking 10 or more cigarettes/day
- Male or female veterans eligible for VA healthcare
- Female nonveterans also eligible
Exclusion Criteria:
- Allergy or hypersensitivity to nicotine or adhesives used in nicotine patch
- Weigh less than 100 lbs
- Lack of interest in stopping smoking
- Pregnant or lactating females or females not practicing acceptable form of
contraception
- Sponsor:
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Yale University
- Dates:
- April 2009
- Last Updated:
- November 16, 2012
- Study HIC#:
- 0804003723
Clinicaltrials.gov ID: NCT00861146


